Serumondo J - Search Results

1

Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.

Gupta N, Manirambona L, Shumbusho F, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Camus G, Grant PM, Kateera F. Gupta N, et al. Among authors: serumondo j. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):542-551. doi: 10.1016/S2468-1253(21)00399-X. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248212 Clinical Trial.

2

Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.

Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S. Umutesi G, et al. Among authors: serumondo j. J Hepatol. 2019 Jun;70(6):1043-1045. doi: 10.1016/j.jhep.2019.03.011. Epub 2019 Apr 1. J Hepatol. 2019. PMID: 30948269 No abstract available.

3

Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda.

Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, Serumondo J, Semakula M, Riedel DJ, Nsanzimana S. Makuza JD, et al. Among authors: serumondo j. BMC Infect Dis. 2019 May 3;19(1):381. doi: 10.1186/s12879-019-4013-4. BMC Infect Dis. 2019. PMID: 31053097 Free PMC article.

4

Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population.

Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, Niyikora J, Serumondo J, Gupta N, Nsanzimana S. Umutesi J, et al. Among authors: serumondo j. BMJ Open. 2019 Jul 3;9(7):e029743. doi: 10.1136/bmjopen-2019-029743. BMJ Open. 2019. PMID: 31272986 Free PMC article.

5

Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program.

Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S. Makuza JD, et al. Among authors: serumondo j. BMC Infect Dis. 2019 Aug 5;19(1):688. doi: 10.1186/s12879-019-4322-7. BMC Infect Dis. 2019. PMID: 31382901 Free PMC article.

6

Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.

Nsanzimana S, Penkunas MJ, Liu CY, Sebuhoro D, Ngwije A, Remera E, Umutesi J, Ntirenganya C, Mugeni SD, Serumondo J. Nsanzimana S, et al. Among authors: serumondo j. Clin Infect Dis. 2021 Nov 2;73(9):e3300-e3307. doi: 10.1093/cid/ciaa701. Clin Infect Dis. 2021. PMID: 32505127

7

Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.

Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Serumondo J, et al. BMC Public Health. 2020 Jun 16;20(1):946. doi: 10.1186/s12889-020-09000-0. BMC Public Health. 2020. PMID: 32546216 Free PMC article.

8

Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study.

Makuza JD, Nisingizwe MP, Rwema JOT, Dushimiyimana D, Habimana DS, Umuraza S, Serumondo J, Ngwije A, Semakula M, Gupta N, Nsanzimana S, Janjua NZ. Makuza JD, et al. Among authors: serumondo j. BMJ Open. 2020 Jul 12;10(7):e036711. doi: 10.1136/bmjopen-2019-036711. BMJ Open. 2020. PMID: 32660951 Free PMC article.

9

Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).

Van Nuil JI, Umutesi G, Shumbusho F, Kateera F, Dushimimana JD, Muvunyi CM, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Kabahizi J, Serumondo J, Makuza JD, Nsanzimana S, Grant P, Gupta N. Van Nuil JI, et al. Among authors: serumondo j. J Viral Hepat. 2021 Jan;28(1):112-120. doi: 10.1111/jvh.13386. Epub 2020 Oct 4. J Viral Hepat. 2021. PMID: 32858774

10

Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan Africa.

Shumbusho F, Liu AF, Kateera F, Kabahizi J, Nsanzaimana S, Serumondo J, Damascene Makuza J, Grant PM, Musabeyezu E, Muvunyi C, Gupta N. Shumbusho F, et al. Among authors: serumondo j. J Viral Hepat. 2021 Apr;28(4):682-686. doi: 10.1111/jvh.13467. Epub 2021 Feb 2. J Viral Hepat. 2021. PMID: 33421247

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters